Key result
Azilsartan provided a significantly greater mean reduction in systolic blood pressure at 5 weeks compared to telmisartan (33.55 vs 31.55 mmHg) in patients with grade I-II essential hypertension.
Why the study?
Does azilsartan 40 mg once daily reduce blood pressure more effectively than telmisartan 40 mg once daily in treatment-naive patients with grade I-II essential hypertension?
RCT (n=80)
Open-label
Random number table
No
Does azilsartan 40 mg once daily reduce blood pressure more effectively than telmisartan 40 mg once daily in treatment-naive patients with grade I-II essential hypertension?
Absolute Event Rate: 33.55% vs 31.55%
p-value: p=<0.05
Azilsartan 40 mg once daily provides a slightly greater reduction in systolic blood pressure at 5 weeks compared to telmisartan 40 mg in patients with grade I-II essential hypertension.
Azilsartan may warrant preference for modestly greater SBP reduction in grade I-II hypertension; extends head-to-head ARB comparisons in treatment-naive patients.
Background: Objectives of the study was to study the effect of Azilsartan 40mg once daily versus Telmisartan 40mg once daily in patients with Grade I-II essential hypertension.Methods: A prospective study was conducted at MGM Medical college and Hospital which included 80 patients in each group with Grade I–II essential hypertension. The sex, age, presenting illness, and family history of the patients were recorded. Investigations such as blood sugar, urine analysis, kidney function test, lipid profile, and ECG were performed before starting the treatment. Any adverse effects during the treatment were noted. Blood pressure was recorded at baseline and during follow-up. One group received Azilsartan 40mg once daily and another group Telmisartan 40mg once daily. Patients were followed-up every week for 5 weeks.Results: Patients receiving Azilsartan 40mg and Telmisartan 40mg showed a significant fall (P <0.05) in systolic (SBP) at the end of fifth week, when compared to baseline and diastolic blood pressure (DBP) significant fall at fourth and fifth week. The difference in fall in SBP and DBP was insignificant between the groups, after first, second and third week (P >0.05). Adverse effects such as Nasopharyngitis, Upper respiratory tract inflammation, Gastroenteritis, headache, dizziness, and fatigue were reported with both drugs.Conclusions: Reduction of blood pressure with Azilsartan and Telmisartan was similar, but fall in blood pressure from baseline was highly significant in both groups.
No takes yet. Share an insight, caveat, or question.
Bhosle et al. (2017) conducted an RCT in Grade I-II essential hypertension (n=80). Azilsartan vs. Telmisartan 40 mg once daily was evaluated on Mean reduction in systolic blood pressure at 5 weeks (p=<0.05). Azilsartan provided a significantly greater mean reduction in systolic blood pressure at 5 weeks compared to telmisartan (33.55 vs 31.55 mmHg) in patients with grade I-II essential hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: